MIF and neoplasm: Genetic, transcriptomic, and proteomic analyses of DDT, CD74:MIF, and CD74:DDT in patients with melanoma can further shed light on the differential expression among varying disease stages, tumor subtypes, mutational statuses, and ICI use.